New Identification Method for Cancerous DNA to Reduce Need for Painful Biopsy Surgery
|
By LabMedica International staff writers Posted on 09 Sep 2024 |
|
Currently, most cancer patients must undergo an invasive and expensive surgical biopsy to remove a tissue sample from their tumor to determine the best treatment options. However, all individuals have small amounts of DNA that circulate freely in their blood, which is not confined within blood cells. In cancer patients, some of this circulating free DNA (ctDNA) originates from their tumors. This ctDNA differs from their normal circulating DNA as it carries mutations that have turned these cells from healthy to cancerous. Thus, ctDNA can provide insights into the cancer's characteristics and indicate which treatments might be most effective. Existing methods to analyze ctDNA are hampered by its low abundance and the presence of a larger quantity of non-cancerous DNA in the blood samples.
Researchers at Heriot-Watt University (Edinburgh, UK) are now developing a novel method to identify cancerous DNA that could reduce the need for painful biopsies. This new technique, known as SNARE, aims to simplify the processing of blood samples to enhance the detection and characterization of cancerous DNA. The team is working on creating both robotic benchtop systems and microfluidic platforms (similar to certain types of lateral flow tests) and will evaluate these methods using blood samples from breast cancer patients to achieve more sensitive ctDNA detection and reduce the need for expensive DNA sequencing.
In patients with advanced-stage cancer, significant amounts of DNA in the bloodstream can often be detected, but by this stage, it is frequently too late for a cure. On the other hand, in early-stage cancer patients, where treatment success rates are higher, over 99% of the circulating free DNA typically originates from healthy cells, complicating the identification of cancerous mutations. The Heriot-Watt research team plans to further develop MicroSNARE, which they have already tested in the lab, with the aim of diagnosing, analyzing, and characterizing tumors at an earlier stage. They also aim to detect cancer recurrence before it can progress and spread. MicroSNARE promises a groundbreaking, less invasive approach to cancer detection, potentially enabling earlier diagnosis and intervention.
Related Links:
Heriot-Watt University
Latest Pathology News
- Genomic Classifier Predicts Benefit From Adding Hormone Therapy to Salvage Prostate Radiation
- Multimodal AI Supports Prostate Cancer Risk Assessment Across Diverse Cohorts
- New AI Model Maps Where Glioblastoma Could Return After Surgery
- Simple Test Could Reduce the Need for Invasive Uterine Cancer Checks
- Tumor Blood Vessel Features May Help Predict Colorectal Cancer Survival
- Multimodal AI Improves Breast Cancer Recurrence Risk Prediction Beyond Standard Genomic Testing
- Machine Learning Cytology Tool Improves Cancer Cell Identification
- CAP Updates Cancer Protocols to Refine Breast Cancer Biomarker Reporting and GIST Molecular Testing
- Tumor Budding Grading May Predict Chemotherapy Benefit in Resected Lung Squamous Cancer
- AI Spatial Analysis of Routine Slides Helps Predict Pancreatic Cancer Recurrence
- Hybrid Computational Imaging Method Improves Digital Pathology Resolution
- FDA Clearance Expands Digital Pathology Options for Clinical Laboratories
- Label-Free Imaging Reveals Hidden Immune Activity in Blood Samples
- AI Tool Improves Prediction of Immunotherapy Response in Lung Cancer
- New Journal Addresses Evolving Needs in Clinical and Translational Pathology
- AI Matches Pathologists in Predicting Breast Cancer Prognosis from Immune Cells
Channels
Clinical Chemistry
view channel
Screening After Pneumococcal Disease May Reveal Undiagnosed Blood Cancer or Immune Disorders
Severe pneumococcal disease requiring hospitalization often presents as pneumonia, particularly in older adults and people with cancer or compromised immune function. Because M protein testing and antibody... Read more
Global Laboratory Survey Underscores Need to Standardize Bone Biomarker Testing
Bone and mineral metabolism biomarkers can complement dual-energy X-ray absorptiometry (DXA) by providing information on disease activity and treatment response. For more than 20 years, standardization... Read more
Label-Free Platform Combines Microfluidics and AI for Circulating Tumor Cell Analysis
Liquid biopsy relies on detecting rare tumor-derived material in blood, but circulating tumor cells (CTCs) are especially difficult to capture because they are vastly outnumbered by normal blood cells.... Read more
Rapid D-Dimer Assay Supports Exclusion and Monitoring of Serious Clotting Conditions
Blood clots can rapidly become life‑threatening and affect approximately 10 million people worldwide each year. During time‑sensitive evaluations, clinicians use D‑dimer testing to help rule out deep vein... Read moreMolecular Diagnostics
view channel
Blood-Based Test Broadens Colorectal Cancer Screening Options
Colorectal cancer is the second-leading cause of cancer-related death in the U.S., yet outcomes improve markedly when the disease is detected through routine screening. Despite this, up to 60 million Americans... Read more
Pooled Saliva PCR Screening Identifies Congenital CMV Missed by Targeted Testing
Congenital cytomegalovirus (cCMV) can be present in newborns who appear healthy and pass routine hearing screening. The infection is one of the most common maternal-to-fetal infections during pregnancy... Read more
Genetic Testing Identifies Inherited Predisposition in Children With Acute Leukemia
Childhood acute leukemia can involve inherited cancer predisposition that is not always apparent at diagnosis. Previous studies estimate that 4% to 10% of children with hematological malignancies carry... Read more
Single Assay Enables Simultaneous Newborn Screening for Three Severe Genetic Disorders
Newborn screening aims to identify serious genetic disorders within the first days of life, when swift intervention can help prevent irreversible harm. Spinal muscular atrophy, severe combined immunodeficiency,... Read moreHematology
view channel
New Donor Genetic Marker May Help Predict Stem Cell Transplant Success
Donor selection for hematopoietic stem cell transplantation plays a major role in relapse risk and survival for patients with blood cancers and other blood disorders. Despite advances in genotyping, uncertainty... Read more
Updated Ferritin Thresholds Improve Detection of Iron Deficiency
Iron deficiency is one of the most common health conditions worldwide, yet its nonspecific symptoms can delay diagnosis for months. Variation in testing practices and ferritin thresholds may contribute... Read more
Immunology
view channel
Blood Test Differentiates Bacterial and Viral Infections in Febrile Infants
Fever in infants younger than 3 months is treated as a medical emergency because infections can become life-threatening while the immune system is still developing. Emergency department teams must quickly... Read more
New Autoantibody Test Targets Pre-Symptomatic Type 1 Diabetes Screening
Type 1 diabetes is often first recognized only after substantial beta-cell destruction, sometimes presenting as diabetic ketoacidosis. Population-scale screening could identify children at elevated risk... Read more
Microbiology
view channel
FDA-Cleared Multiplex PCR Test Detects 13 Respiratory Pathogens in a Single Sample
Respiratory tract infections can be difficult to distinguish at presentation because many cause overlapping, nonspecific symptoms and are initially grouped as influenza-like illnesses. Causes span a range... Read more
One-Hour Molecular Panel Expands Bloodstream Infection Testing for Gram-Negative Pathogens
Bloodstream infections can progress rapidly and lead to sepsis, organ failure, and death. In the United States, about 1.7 million adults develop sepsis each year, and at least 350,000 die during hospitalization... Read more
FDA Clears Rapid Phenotypic Antimicrobial Susceptibility System for Positive Blood Cultures
Bloodstream infections require prompt treatment, but antimicrobial susceptibility results often lag behind a positive blood culture. Conventional testing can take another 24 to 48 hours after a culture... Read more
New Urine Test Expands Mycotoxin Analysis to 31 Markers for Broader Exposure Assessment
Clinical evaluation of mold exposure increasingly relies on urinary mycotoxin testing, but limited marker coverage and metabolite masking can make results more difficult to interpret. Broader analysis... Read moreTechnology
view channel
Laser-Based Swab Analysis Shows Promise for Detecting Disease-Linked Odor Patterns
Disease-related changes in volatile organic compounds can alter body odor, producing measurable patterns in exhaled breath and bodily fluids. Current analytical methods can be complex, time-consuming,... Read more
Laser-Enhanced Assay Boosts Sensitivity for Colorectal Cancer Biomarker Detection
Colorectal cancer is the third most commonly diagnosed cancer and the second leading cause of cancer-related death worldwide. Early detection remains critical, but cancer biomarkers can produce only faint... Read more
Industry
view channel
Collaboration Combines AI Cognitive Assessment and RNA Blood Testing for Earlier Alzheimer’s Detection
Alzheimer’s disease is often identified only after substantial neurodegeneration, partly because current diagnostic pathways are fragmented and difficult to scale. As treatment shifts toward earlier intervention,... Read more
Mayo Clinic Laboratories and Pathology Asia Expand Genomic Testing Across Asia-Pacific
Mayo Clinic Laboratories and Pathology Asia Holdings (PAH), together with subsidiary LifeStrands Genomics, announced a strategic investment and collaboration focused on expanding access to advanced diagnostics... Read more
